Study to Clarify Radiation Benefits in Mesothelioma Patients

radiation-therapy-machine-cancer

An upcoming phase III clinical trial involving the National Cancer Institute should clarify the still-debatable benefits of using radiotherapy in combination with aggressive surgery for patients with pleural mesothelioma.

The trial will be the first multicenter, randomized study measuring both safety and potential survival benefits of intensity-modulated radiation therapy (IMRT) and pencil-beam scanning with pleurectomy and decortication surgery and chemotherapy.

The trial is sponsored by NRG Oncology and will involve several mesothelioma specialty centers across the country. The goal is to enroll a combined 150 patients.

Only half will receive IMRT after surgery, giving researchers a clear comparison.

“It will be an important trial. At this point, the role of radiation with mesothelioma is not entirely proven,” Dr. Vivek Verma, radiologist at Allegheny General Hospital in Pittsburgh, told The Mesothelioma Center at Asbestos.com. “It’s hard, with a rare cancer like this, to get adequately powered randomized studies to evaluate the benefit. This next trial should provide some answers.”

Benefits of IMRT with Surgery Still Debated

Although radiation therapy is still being used in mesothelioma treatment, its use remains selective and sometimes controversial.

Results from earlier, smaller studies have been mixed, often questioning the side-effect tradeoff and any survival benefit. Cases of severe toxicities have been documented following radiotherapy for pleural mesothelioma.

Guidelines from the National Comprehensive Cancer Network (NCCN), which many centers adhere to, are equivocal in recommending radiotherapy for mesothelioma.

“RT under such circumstances after P/D [pleurectomy and decortication] is usually not recommended. Hemithoracic IMRT after P/D may be considered in centers with experience and expertise in these methods,” the NCCN guidelines read.

NRG Oncology Study Provides Perspective

The upcoming trial comes in the wake of a recently published study that will serve as a lead-in endorsement for anyone questioning the safety aspect.

Practical Radiation Oncology published the results, a retrospective compilation of 10 smaller studies that looked at the use of IMRT at various levels after lung-sparing surgery.

“Our study provided a framework, a solid foundation for the randomized trial,” lead-author Roshal Patel, MD Anderson Cancer Center in Houston, told The Mesothelioma Center at Asbestos.com. “Let’s see what prospective data (from the next study) has to say. If it shows patients having better outcomes with these advanced modalities, we can move in that direction of treatment.”

Verma also was part of the latest study.

In the various earlier studies of radiotherapy, median progression-free survival for pleural mesothelioma ranged from 12 to 16 months and median overall survival from 19 to 28 months.

Only 1.5% of the patients experienced grade 4 or grade 5 pneumonitis, an inflammation of the lungs that could lead to permanent scaring.

The incidence of grade 3 pneumonitis ranged from 0% to 16%. In eight of the 10 studies, the grade 3 rate of pneumonitis was less than 9%.

Researchers said the systematic review “produced relatively few higher-grade toxicities with reasonable disease-related outcomes.”

“Our study suggests that this approach is safe and can be considered in well-selected patients,” the authors said. “Other guidelines continued to move toward this conclusion, but acknowledge that evidence is still limited.”

In the earlier studies, one had a two-year survival rate of 59%, while another was only 35%.

Proponents Believe IMRT Has Benefits

The recent change in surgical philosophy for mesothelioma has contributed to the debate over radiation therapy.

A decade ago, thoracic surgeons often were using the more aggressive extrapleural pneumonectomy — removing the entire diseased lung — for maximum tumor cell resection, allowing the delivery of high doses of radiation without serious toxicity risk.

In recent years, though, most of the surgeries have been pleurectomy and decortication — sparing the lung — which requires more radiation to avoid collateral damage.

Proponents believe that when combined with surgery and chemotherapy, IMRT can improve survival time, relieve pain and help prevent remaining tumor cells from moving into new areas.

Detractors point to the potential side effects, including inflammation of the lining around the heart, shortness of breath, fluid buildup and calcification of the lymph nodes.

Radiation often is recommended in combination with chemotherapy for patients who are not candidates for surgery.

“The management of mesothelioma continues to evolve, both in the surgical and radiological realm,” Verma said. “We don’t definitively know the benefit [of radiotherapy]. This next trial should provide an answer one way or another.”

Medical Staff Icon
Connect with a Mesothelioma Doctor Find a Top Specialist Near You
Get Help Now

Senior Content Writer

Tim Povtak is an award-winning writer with more than 30 years of reporting national and international news. His specialty is interviewing top mesothelioma specialists and researchers, reporting the latest news at mesothelioma cancer centers and talking with survivors and caregivers.

3 Cited Article Sources

The sources on all content featured in The Mesothelioma Center at Asbestos.com include medical and scientific studies, peer-reviewed studies and other research documents from reputable organizations.

  1. Patel, R. et al. (2020, February 20). Disease-Related Outcomes and Toxicities of Intensity-Modulated Radiation Therapy Following Lung-Sparing Pleurectomy for Malignant Pleural Mesothelioma: A Systematic Review.
    Retrieved from: https://www.sciencedirect.com/science/article/pii/S1879850020300424
  2. ClinicalTrials.gov. (2019, November 8). Testing the Addition of Targeted Radiation Therapy to Surgery and the Usual Chemotherapy Treatment (Pemetrexed and Cisplatin) for Stage I-IIIA Malignant Pleural Mesothelioma.
    Retrieved from: https://clinicaltrials.gov/ct2/show/NCT04158141
  3. National Comprehensive Cancer Network. (n.d.) NCCN Guidelines. Retrieved from: https://www.nccn.org/professionals/physician_gls/default.aspx#site

More on This Topic

Get Your Free Mesothelioma Guide Chat live with a patient advocate now